{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.8","upperLimit":"15.8","value":"7.6"},{"comment":"NA: Confidence Interval could not be calculated for only 1 participant.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"0.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"79"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"description":"These are the participants who achieved CR or CRi and then proceeded to HSCT while in remission prior to Month 6 response assessment","dispersionType":"95% Confidence Interval","groups":[{"description":"Pediatric patients with relapsed or refractory B-cell ALL who were treated with single dose of tisagenlecleucel (CTL019).","id":"OG000","title":"Main Cohort: Single Dose of CTL019"},{"description":"Pediatric B-ALL patients who are very high risk at first relapse.","id":"OG001","title":"Cohort 1: Single Dose of CTL019"}],"paramType":"NUMBER","populationDescription":"FAS: The Full analysis set comprised all patients who received infusion of tisagenlecleucel.","reportingStatus":"POSTED","timeFrame":"6 months","title":"Percentage of Participants Who Achieved CR or CRi and Then Proceeded to Hematopoietic Stem Cell Transplantation (HSCT) While in Remission Prior to Month 6 Resoonse","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}